Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Link on the Current State of Treatment For Pediatric Cancer

Michael Link, MD
Published: Monday, Oct 08, 2018



Michael Link, MD, professor, Pediatrics, Stanford Cancer Institute, and a 2018 Giant of Cancer Care® in Pediatric Oncology discusses the current paradigm for treatment in pediatric cancer.

There are several unmet needs in this space, Link says. Brain tumors and central nervous system malignancies are an area where answers are still needed. Patients with metastatic solid tumors are still resistant to therapy and very difficult to cure. Neuroblastoma, a common solid tumor in toddlers, has not seen the needle move far despite very intensive treatment strategies. There is still a long way to go in these settings.

Some of the more exciting recent developments, Link says, are with immunotherapy and chimeric antigen receptor T-cell therapy. The fact that it is possible to manipulate and genetically engineer a patient’s own immune system has resulted in dramatically improved outcomes. This has been particularly effective in recurrent leukemia. A common strategy in pediatric cancer has been to find a successful therapy in relapsed disease and move it to an earlier setting, Link adds.


Michael Link, MD, professor, Pediatrics, Stanford Cancer Institute, and a 2018 Giant of Cancer Care® in Pediatric Oncology discusses the current paradigm for treatment in pediatric cancer.

There are several unmet needs in this space, Link says. Brain tumors and central nervous system malignancies are an area where answers are still needed. Patients with metastatic solid tumors are still resistant to therapy and very difficult to cure. Neuroblastoma, a common solid tumor in toddlers, has not seen the needle move far despite very intensive treatment strategies. There is still a long way to go in these settings.

Some of the more exciting recent developments, Link says, are with immunotherapy and chimeric antigen receptor T-cell therapy. The fact that it is possible to manipulate and genetically engineer a patient’s own immune system has resulted in dramatically improved outcomes. This has been particularly effective in recurrent leukemia. A common strategy in pediatric cancer has been to find a successful therapy in relapsed disease and move it to an earlier setting, Link adds.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x